Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 19/20 | 0.81 |
| ▸ | RORA | P35398 | 2/20 | 0.65 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19165251 | 0.91 | RORC (0.84) | RORCRORANR1H4 | |
| SCHEMBL19165424 | 0.89 | RORC (0.81) | RORCRORANR1H4 | |
| SCHEMBL29832886 | 0.89 | RORC (1.00) | RORCRORANR1H4 | |
| SCHEMBL22451906 | 0.89 | RORC (1.00) | RORCRORANR1H4 | |
| SCHEMBL19165858 | 0.89 | RORC (0.81) | RORCRORANR1H4 | |
| SCHEMBL24032689 | 0.89 | RORC (0.76) | RORCRORANR1H4 | |
| SCHEMBL22451994 | 0.88 | RORC (1.00) | RORCRORANR1H4 | |
| SCHEMBL22451941 | 0.87 | RORC (1.00) | RORCRORANR1H4 | |
| SCHEMBL19165254 | 0.86 | RORC (1.00) | RORCRORANR1H4 | |
| SCHEMBL19165545 | 0.85 | RORC (0.74) | RORCRORANR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-03 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-27 | — | — | US | disclosed |
| WO-2017127442-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192454-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | RORC 3/4885RORA 1/4885NR1H4 20/4885 |
| US-20210161837-A1 | METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS | RORA, RORB, RORC | RORC 3/4885RORA 1/4885NR1H4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.